Albendazole inhibits colon cancer progression and therapy resistance by targeting ubiquitin ligase RNF20.

ABSTRACT:

Background

The repurposing of FDA-approved drugs for anti-cancer therapies is appealing due to their established safety profiles and pharmacokinetic properties and can be quickly moved into clinical trials. Cancer progression and resistance to conventional chemotherapy remain the key hurdles in improving the clinical management of colon cancer patients and associated mortality.

Methods

High-throughput screening (HTS) was performed using an annotated library of 1,600 FDA-approved drugs to identify drugs with strong anti-CRC properties. The candidate drug exhibiting most promising inhibitory effects in in-vitro studies was tested for its efficacy using in-vivo models of CRC progression and chemoresistance and patient derived organoids (PTDOs).

Results

Albendazole, an an

SUBMITTER: Fatima I 

PROVIDER: S-EPMC10951408 | biostudies-literature | 2024 Apr

REPOSITORIES: biostudies-literature